When was NextBio founded?

NextBio was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Where is NextBio located?

NextBio is headquartered in Santa Clara, United States.

How many employees does NextBio have?

As of Jul 31, 2026, the latest employee count at NextBio is 25.

Is NextBio a funded company?

NextBio is a funded company, having raised a total of $28.3M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 11, 2005.

When was the latest funding round of NextBio?

NextBio's latest funding was a $***** Grant (prize money) round on Jul 01, 2010, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.9B in funding in 2026 to date.

Where does NextBio rank among its competitors?

NextBio ranks 51st amongst 665 active competitors, of which 140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Relation, which secured $36.2M in Nov, 2025.

Who are the top competitors of NextBio?

NextBio's top competitors include Benchling, Helix and DNAnexus. Among them, Relation secured the most recent funding round in November, 2025.

NextBio - 2026 Company Profile, Team, Funding & Competitors

NextBio is an acqui-hired company based in Santa Clara (United States), founded in 2004 by Mostafa Ronaghi, Saeid Akhtari and Ilya Kupershmidt. It operates as a NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications.. NextBio has raised $28.3M in funding from Rising Tide Fund. The company has 665 active competitors, including 140 funded and 38 that have exited. Its top competitors include companies like Benchling, Helix and DNAnexus.

Company Details

NextBio, a software company that provides a platform for life science researchers to search, discover and share knowledge across public and proprietary data. The NextBio Platform is an ontology-based semantic framework that connects highly heterogeneous data and textual information. The semantic framework is based on gene, tissue, disease and compound ontologies. The enterprise version of the NextBio platform is being used in life science R&D and drug development by researchers and clinicians at Pharma Companies. It has been acquired by Illumina.

Website: nextbio.com
Social

Key Metrics

Founded Year

2004

Location

Santa Clara, United States

Stage

Acqui-Hired

Total Funding

$28.3M in 10 rounds

Latest Funding Round

Grant (prize money), Jul 01, 2010, $*****

Investors

Rising Tide Fund & 7 more

Ranked

51^st among 665 active competitors

Employee Count

25 as on Jul 31, 2026

Similar Companies

Benchling & 832 more

View NextBio's full profile

NextBio has raised a total funding of $28.3M over 10 rounds. Its first funding round was on Feb 11, 2005. Its latest funding round was a Grant (prize money) round on Jul 01, 2010 for $*****. 1 investor participated in its latest round. NextBio has 8 institutional investors.

Here is the list of recent funding rounds of NextBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2010	8357165	Grant (prize money)	8892003	5142831	2857192	1967754
Sep 17, 2009	8149944	Series C	1857834	8874907	3878264	8564191
Jun 24, 2009	3501951	Series C	7680752	7152593	4357948	8759176

Access funding benchmarks and valuations. Sign up today!

View details of NextBio's funding rounds and investors

The founders of NextBio are Mostafa Ronaghi, Saeid Akhtari and Ilya Kupershmidt.

Here are the details of NextBio's key team members:

Mostafa Ronaghi: Former Co-Founder of NextBio and founder of 3 other companies, ParAllele BioScience, GRAIL and Cellanome. They are also an angel investor in 4 startups.
Saeid Akhtari: Co-Founder of NextBio and founder of 1 other company. They serve on the board of 1 company.
Ilya Kupershmidt: Co-Founder of NextBio.

View details of NextBio's Founder profiles and Board Members

NextBio's employee count trend

NextBio has 25 employees as of Jul 26. Here is NextBio's employee count trend over the years:

Uncover NextBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NextBio include Benchling, Helix and DNAnexus. Here is the list of Top 10 competitors of NextBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Benchmark & 29 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Catalio Capital Management, Koch Disruptive Technologies ... & 14 others	65/100
6th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, Horizons Ventures & 11 others	65/100
7th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
8th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
9th	Somite 2023, Boston (United States), Series A	AI-driven platform to produce human tissue for cell-based therapies	$60M	Khosla Ventures, Astellas Venture Management ... & 13 others	63/100
10th	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Xeraya Capital & 39 others	62/100
51st	NextBio 2004, Santa Clara (United States), Acqui-Hired	NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications.	$28.3M	Rising Tide Fund, RONA Holdings & 6 others	45/100